Business Description
Imaging Biometrics Ltd. is a healthcare technology company operating across the United Kingdom, Switzerland, the European Union, and the United States, offering a suite of medical imaging software tools that help clinicians assess conditions such as stroke, dementia, kidney stones, and liver disease. The company also develops IB003, an experimental drug currently in early-stage clinical trials as a potential treatment for glioblastoma, a severe form of brain cancer. Formerly known as IQ-AI Limited, the company rebranded in May 2025 and has been incorporated since 1965, with its registered base in Saint Helier, Jersey.
